[{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"IDG Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Allorion Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Allorion Therapeutics \/ IDG Capital","highestDevelopmentStatusID":"4","companyTruncated":"Allorion Therapeutics \/ IDG Capital"},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"INCE Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"ARTS-011","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Allorion Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Allorion Therapeutics \/ INCE Capital","highestDevelopmentStatusID":"5","companyTruncated":"Allorion Therapeutics \/ INCE Capital"},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Allorion Therapeutics","amount2":0.54000000000000004,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.54000000000000004,"dosageForm":"","sponsorNew":"Allorion Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"Allorion Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Allorion Therapeutics","sponsor":"Avenzo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"AVZO-021","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Allorion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Allorion Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Allorion Therapeutics \/ Avenzo Therapeutics"}]